Skip to content
Screener

Savara SVRA In Process Research And Development

In Process Research And Development at other companies

TuHURA Biosciences, Inc. logo
TuHURA Biosciences, Inc.HURA
$11.28M
NuScale Power logo
NuScale PowerSMR
$16.9M0.0%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$625K
Corvex logo
CorvexMOVE
$822K-65.2%
Accenture logo
AccentureACN
$204.33M-29.0%
Campbell Soup logo
Campbell SoupCPB
$6M-82.9%

Other financials

Income statement

See full
Revenue-
Operating income-$41.0M-30.3%
Net income-$40.2M-32.3%
EPS (diluted)-$0.16-14.3%

Balance sheet

See full
Cash & equivalents$41.8M+140%
Total debt$31.2M+5.2%
Total equity$143.7M+19.2%
Total assets$192.1M+17.3%

Cash flow

See full
Operating cash flow-$29.7M-13.3%
CapEx$222.0K+1,380%
Free cash flow-$30.0M-14.1%

Valuation

See full
Market cap$1.17B+152%
Enterprise value$1.16B+143%

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-105.5%+7.0pp
Debt / equity0.2×0.0×
Current ratio10.1×-0.9×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept svra:InProcessResearchAndDevelopment.

The source filing: Savara’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344585
Line itemJune 30, 2026December 31, 2025
Prepaid expenses and other current assets5,2835,914
Total current assets178,317241,616
Property and equipment, net641100
In-process R&D11,28911,636
Other non-current assets1,89184
Total assets$192,138$253,436
Liabilities and stockholders' equity
Current liabilities:

Cover / Front Matter

FAQ

What is Savara's in process research and development?
Savara (SVRA) reported in process research and development of $11.29M in Q2 2026.
How has Savara's in process research and development changed year-over-year?
Savara's in process research and development decreased by 2.9% year-over-year, from $11.63M to $11.29M.
What is the long-term trend for Savara's in process research and development?
Over 5 years (2020 to 2025), Savara's in process research and development has grown at a -1.0% compound annual growth rate (CAGR), from $12.22M to $11.64M.
What does in process research and development mean?
This represents the capitalized value of research and development projects acquired through business combinations that have not yet reached technological feasibility. It reflects the investment in pipeline assets that are currently undergoing clinical trials or regulatory review. Monitoring this balance provides insight into the company's commitment to future product commercialization and the potential long-term value of its therapeutic pipeline.

Ask your AI about Savara's in process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude